NANOSPHERES AS ANTICANCER AGENTS: REPROGRAMMING THE TUMOR MICROENVIRONMENT (TME) FOR ENHANCED CANCER THERAPY

The effectiveness of standard cancer treatment methods including chemotherapy and radiotherapy and immunotherapy becomes limited because of the hostile and adaptive characteristics of the Tumor Microenvironment (TME) rather than natural cancer cell resistance. The TME functions as an obstacle to treatment because it contains abnormal blood vessels and extreme low oxygen levels and acidic conditions and thickened and linked extracellular matrix (ECM). The research report describes how nano-oncology has evolved from using drug delivery systems that passively release medications to active TME modification platforms. The research presents a detailed study of intelligent nanospheres which transform the TME from its current state of drug resistance and immunosuppression into an environment that supports drug penetration and immune system activation. The nanocarriers achieve their purpose through three main actions which include generating oxygen within tumors to fight hypoxia and using biomimetic approaches to transform TAMs and enzymatic methods to break down stromal barriers. The advanced nanocarriers present a new method to fight drug resistance through their ability to generate oxygen in tumors and transform TAMs and break down stromal barriers. The research investigates pharmaceutical system development through microfluidic models and advanced characterization methods to verify their suitability for medical use. The report assesses the clinical development of radio-enhancers (NBTXR3) and photothermal agents (AuroLase) and theranostic radiosensitizers (AGuIX) through essential clinical tests to demonstrate their ability to transform current treatment standards. The document presents a future-oriented view of Artificial Intelligence (AI) assisted design and hybrid systems to establish that oncology will succeed through environmental transformation rather than cancer cell elimination.